<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:29:59Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8485230" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8485230</identifier>
        <datestamp>2021-10-08</datestamp>
        <setSpec>svn</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Stroke Vasc Neurol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Stroke Vasc Neurol</journal-id>
              <journal-id journal-id-type="hwp">svnbmj</journal-id>
              <journal-id journal-id-type="publisher-id">svn</journal-id>
              <journal-title-group>
                <journal-title>Stroke and Vascular Neurology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2059-8696</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8485230</article-id>
              <article-id pub-id-type="pmcid">PMC8485230</article-id>
              <article-id pub-id-type="pmc-uid">8485230</article-id>
              <article-id pub-id-type="pmid">33526633</article-id>
              <article-id pub-id-type="pmid">33526633</article-id>
              <article-id pub-id-type="publisher-id">svn-2020-000493</article-id>
              <article-id pub-id-type="doi">10.1136/svn-2020-000493</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Smoking influences outcome in patients who had thrombolysed ischaemic stroke: the ENCHANTED study</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-79441403" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3859-9672</contrib-id>
                  <name>
                    <surname>Sun</surname>
                    <given-names>Lingli</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-54275038" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6105-1720</contrib-id>
                  <name>
                    <surname>Song</surname>
                    <given-names>Lili</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-57595715" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9032-5348</contrib-id>
                  <name>
                    <surname>Yang</surname>
                    <given-names>Jie</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-54614761" contrib-type="author">
                  <name>
                    <surname>Lindley</surname>
                    <given-names>Richard I</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-54614693" contrib-type="author">
                  <name>
                    <surname>Robinson</surname>
                    <given-names>Thompson</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-54614801" contrib-type="author">
                  <name>
                    <surname>Lavados</surname>
                    <given-names>Pablo M</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-78351726" contrib-type="author">
                  <name>
                    <surname>Delcourt</surname>
                    <given-names>Candice</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-54614989" contrib-type="author">
                  <name>
                    <surname>Arima</surname>
                    <given-names>Hisatomi</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-80410162" contrib-type="author">
                  <name>
                    <surname>Ovbiagele</surname>
                    <given-names>Bruce</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-54276276" contrib-type="author">
                  <name>
                    <surname>Chalmers</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-57595757" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Anderson</surname>
                    <given-names>Craig S</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-54296828" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1684-7076</contrib-id>
                  <name>
                    <surname>Wang</surname>
                    <given-names>Xia</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">The George Institute for Global Health</institution>, <institution>Peking University Health Science Centre</institution>, <addr-line content-type="city">Beijing</addr-line>, <country>China</country></aff>
              <aff id="aff2"><label>2</label><institution>The George Institute for Global Health, University of New South Wales</institution>, <addr-line content-type="city">Sydney</addr-line>, <addr-line content-type="state">NSW</addr-line>, <country>Australia</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Department of Neurology</institution>, <institution>The First Affiliated Hospital of Chengdu Medical College</institution>, <addr-line content-type="city">Chengdu</addr-line>, <country>China</country></aff>
              <aff id="aff4"><label>4</label><institution>Faculty of Medicine, University of Sydney</institution>, <addr-line content-type="city">Sydney</addr-line>, <addr-line content-type="state">NSW</addr-line>, <country>Australia</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Department of Cardiovascular Sciences and NIHR Biomedical Research Unit for Cardiovascular Sciences</institution>, <institution>University of Leicester</institution>, <addr-line content-type="city">Leicester</addr-line>, <country>UK</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Clínica Alemana de Santiago</institution>, <institution>Universidad del Desarrollo</institution>, <addr-line content-type="city">Santiago de Chile</addr-line>, <addr-line content-type="state">Region Metropolitana de S</addr-line>, <country>Chile</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Department of Preventive Medicine and Public Health, Faculty of Medicine</institution>, <institution>Fukuoka University</institution>, <addr-line content-type="city">Fukuoka</addr-line>, <country>Japan</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">San Francisco VA Healthcare System</institution>, <institution>University of California</institution>, <addr-line content-type="city">San Francisco</addr-line>, <addr-line content-type="state">California</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Professor Craig S Anderson; <email>canderson@georgeinstitute.org.au</email>
</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>2</month>
                <year>2021</year>
              </pub-date>
              <volume>6</volume>
              <issue>3</issue>
              <fpage>395</fpage>
              <lpage>401</lpage>
              <history>
                <date date-type="received">
                  <day>09</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
                <date date-type="rev-recd">
                  <day>24</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>06</day>
                  <month>12</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2021-02-01">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="svn-2020-000493.pdf"/>
              <abstract>
                <sec>
                  <title>Background and purpose</title>
                  <p>As studies vary in defining the prognostic significance of smoking in acute ischaemic stroke (AIS), we aimed to determine the relation of smoking and key outcomes in patient participants who had thrombolysed AIS of the international quasi-factorial randomised Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Post-hoc analyses of ENCHANTED, an international quasi-factorial randomised evaluation of intravenous alteplase-dose comparison and levels of blood pressure control in patients who had thrombolysed AIS. Multivariable logistic regression models with inverse probability of treatment weighting (IPTW) propensity scores were used to determine associations of self-reported smoking status and clinical outcomes, according to 90-day modified Rankin Scale (mRS) scores and symptomatic intracerebral haemorrhage (sICH).</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Of 4540 patients who had an AIS, there were 1008 (22.2%) current smokers who were younger and predominantly male, with more comorbidities of hypertension, coronary artery disease, atrial fibrillation and diabetes mellitus, and greater baseline neurological impairment, compared with non-smokers. In univariate analysis, current smokers had a higher likelihood of a favourable shift in mRS scores (OR 0.88, 95% CI 0.77 to 0.99; p=0.038) but this association reversed in a fully adjusted model with IPTW (adjusted OR 1.15, 95% CI 1.04 to 1.28; p=0.009). A similar trend was also apparent for dichotomised poor outcome (mRS scores 2–6: OR 1.18, 95% CI 1.05 to 1.33; p=0.007), but not with the risk of sICH across standard criteria.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>Smoking predicts poor functional recovery in patients who had thrombolysed AIS.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT01422616" ext-link-type="uri">NCT01422616</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>stroke</kwd>
                <kwd>thrombolysis</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Stroke Association of the United Kingdom</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>TSA 2012/01</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1020462</award-id>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Council for Scientific and Technological Development of Brazil</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>467322/2014-7</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>In addition to a two-fold increased risk of acute ischaemic stroke (AIS) in the general population,<xref rid="R1" ref-type="bibr">1–4</xref> cigarette smoking influences the prognosis from this illness and risk of recurrent vascular events.<xref rid="R5" ref-type="bibr">5–7</xref> Intravenous alteplase has an established net benefit in patients who have AIS across a wide range of characteristics,<xref rid="R8" ref-type="bibr">8–11</xref> but the interaction with smoking on recovery is controversial. Several studies suggest better outcomes in patients who had thrombolysed AIS who smoke,<xref rid="R12" ref-type="bibr">12</xref> possibly by modifying platelet function,<xref rid="R13" ref-type="bibr">13 14</xref> altering clot dynamics and enhancing reperfusion.<xref rid="R15" ref-type="bibr">15 16</xref> However, selection bias and residual confounding limit the conclusions that can be drawn from such data.<xref rid="R17" ref-type="bibr">17</xref> Recent post-hoc analyses of the efficacy and safety of MRI-based thrombolysis in wake-up stroke trial have shown that smoking does not modify the effect of intravenous thrombolysis in 486 patients who had an AIS with an unknown time of symptom onset and diffusion-weighted imaging-fluid attenuation inversion recovery mismatch on brain MRI.<xref rid="R18" ref-type="bibr">18</xref> Herein, we present analyses of the international Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) to help resolve conflicting results across studies concerning the prognostic significance of smoking in patients who had thrombolysed AIS.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <sec id="s2-1">
                <title>Study design</title>
                <p>ENCHANTED was an international, 2×2 partial-factorial, multicentre, prospective, randomised, open-label, blinded-endpoint trial, which evaluated the effects of low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase (n=3310), and intensive versus guideline-recommended blood pressure (BP) lowering (n=2227) in 4587 patients who had thrombolysis-eligible AIS.<xref rid="R19" ref-type="bibr">19–23</xref>
</p>
              </sec>
              <sec id="s2-2">
                <title>Clinical assessment and outcomes</title>
                <p>Key demographic and clinical characteristics were recorded at the time of patient enrolment, with current smoking status obtained by self-report. Clinical outcomes were assessed at 90 days by trained investigators blind to study treatment. The primary outcome was functional status, defined by an ordinal shift in the distribution of the full range of scores on the modified Rankin Scale (mRS). Other outcomes were according to dichotomous scores on the mRS (1–6 vs 0; 2–6 vs 0–1; 3–6 vs 0–2; 4–6 vs 0–3; 5–6 vs 0–4; 6 vs 0–5), and death or neurological deterioration according to scores on the National Institutes of Health Stroke Scale (NIHSS) in 24 hours and 7 days. Safety outcomes were symptomatic intracranial haemorrhage (sICH), any ICH, any clinician reported ICH, any adjudicated ICH and any fatal ICH. The key measure of sICH was from the Safe Implementation of Thrombolysis in Stroke-Monitoring Study, defined as type 2 parenchymal ICH (&gt;30% of the infarcted area affected by haemorrhage with mass effect or extension outside the infarct) together with either neurological deterioration (≥4 points increase in NIHSS score) or death within 24–36 hours.<xref rid="R24" ref-type="bibr">24</xref> Other criteria used to further evaluate symptomatic ICH were definitions from the National Institute of Neurological Disorders and Stroke (NINDS), second and third European Cooperative Acute Stroke Studies and third International Stroke Trial.<xref rid="R25" ref-type="bibr">25–28</xref>
</p>
              </sec>
              <sec id="s2-3">
                <title>Statistical analysis</title>
                <p>As patient characteristics were expected to differ between smokers and non-smokers, we calculated a propensity score to estimate individual probability of being a smoker based on the following baseline variables: sex, age, ethnicity (Asian vs non-Asian), systolic BP, NIHSS score, estimated premorbid mRS score (0 vs 1), presence of vascular risk factors (hypertension, coronary artery disease, other heart diseases, atrial fibrillation, diabetes mellitus or hypercholesterolaemia) and medications (anticoagulation, antiplatelet therapy, glucose lowering and lipid lowering agents). The inverse probability of treatment weighting (IPTW) adjustment for baseline imbalances<xref rid="R29" ref-type="bibr">29</xref> was examined using absolute standardised differences in covariate means.<xref rid="R30" ref-type="bibr">30</xref> Stabilised weights,<xref rid="R31" ref-type="bibr">31</xref> used to reduce variance in the estimates of the effect of smoking, were incorporated into logistic regression models to determine associations of smoking and outcomes. Data were presented with OR and 95% CI, with a standard level of significance set at p&lt;0.05. All analyses were undertaken using SAS software (V.9.3).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <p>Overall, 4540 patients who had thrombolysed AIS were included in these analyses, of whom 1008 (22.2%) were current smokers. <xref rid="T1" ref-type="table">Table 1</xref> shows that compared with non-smokers, current smokers were younger, predominantly male, had more cardiovascular risk factors of hypertension, coronary artery or other heart disease, atrial fibrillation, diabetes mellitus and hypercholesterolaemia, presented with greater neurological impairment, and were more likely to have AIS with a final diagnosis of either large-vessel occlusion or cardioembolism. Time from symptom onset to alteplase administration was comparable between the two groups, but smokers were less likely to receive in-hospital nasogastric feeding, early mobilisation, compression stockings and subcutaneous heparin treatment.</p>
              <table-wrap position="float" id="T1">
                <label>Table 1</label>
                <caption>
                  <p>Baseline patient characteristics and management by smoking status</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Variables</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Non-smoking<break/>(N=3532)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Smoking<break/>(N=1008)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">P value</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Time from symptom onset to randomisation, min</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2.9 (2.2–3.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2.9 (2.2–3.8)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.680</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Time from symptom onset to intravenous alteplase, min</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">170 (129–217)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">175 (131–224)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.068</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age, years</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">68.2 (12.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">61.5 (11.2)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Female</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1583 (44.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">132 (13.1)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Asian</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2245 (63.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">282 (28.0)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Systolic blood pressure</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">154 (19)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">152 (19)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Diastolic blood pressure</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">86 (13)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">88 (13)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Heart rate</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">79 (16)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">79 (14)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.549</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">NIHSS score</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8 (5–13)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7 (4–12)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">GCS</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">15 (13–15)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">15 (14–15)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Medical history</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Hypertension</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2360/3532 (66.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">573/1008 (56.8)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Stroke</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">653/3532 (18.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">168/1008 (16.7)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.185</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Coronary artery disease</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">534/3532 (15.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">109/1008 (10.8)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Other heart diseases</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">232/3532 (6.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">49/1008 (4.9)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.047</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Atrial fibrillation</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">698/3528 (19.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">107/1008 (10.6)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Diabetes mellitus</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">755/3532 (21.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">170/1008 (16.9)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.002</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Hypercholesterolaemia</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">572/3532 (16.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">132/1008 (13.1)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.017</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Premorbid symptom-free (mRS 0)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2905/3530 (82.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">869/1007 (86.3)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.003</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Antihypertensive agent(s)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1698/3532 (48.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">373/1008 (37.0)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Statin/other lipid-lowering</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">708/3529 (20.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">135/1007 (13.4)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Aspirin/other antiplatelet agent(s)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">831/3530 (23.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">153/1007 (15.2)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Warfarin anticoagulation</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">90/3530 (2.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">10/1007 (1.0)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.003</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Glucose lowering agent(s)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">484/3530 (13.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">98/1007 (9.7)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" colspan="4" rowspan="1">Pathological subtype</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Large-artery occlusion</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1377/3394 (40.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">427/963 (44.3)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Cardioembolism</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">781/3394 (23.0)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">276/963 (28.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Small-vessel or perforator disease</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">684/3394 (20.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">112/963 (11.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Other/uncertain aetiology</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">552/3394 (16.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">148/963 (15.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Management</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Intubation and ventilation</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">181/3480 (5.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">46/988 (4.7)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.491</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Nasogastric feeding</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">636/3479 (18.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">153/988 (15.5)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.042</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Physiotherapy mobilisation</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1579/3479 (45.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">391/988 (39.6)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Compression stockings</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">320/3478 (9.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">62/988 (6.3)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.004</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Subcutaneous heparin</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">710/3532 (20.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">151/1008 (15.0)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Antithrombotic agent in first 24 hours</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">593/3522 (16.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">152/1007 (15.1)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.188</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Haemicraniectomy</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">34/3480 (1.0)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">13/988 (1.3)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.357</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Intensive care unit admission</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">785/3479 (22.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">216/988 (21.9)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.641</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Rehabilitation</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1725/3480 (49.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">495/988 (50.1)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.768</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Decision to withdrawal active care</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">97/3481 (2.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">14/988 (1.4)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.015</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T1_FN1">
                    <p>Data are n/N (%), mean (SD) or median (IQR).</p>
                  </fn>
                  <fn id="T1_FN2">
                    <p>GCS, Glasgow Coma Scale; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Distributions of baseline covariates were well balanced following application of propensity scores; all post-IPTW absolute standardised differences were within an acceptable margin of 0.1 (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S1</xref>). Although the proportional odds assumption was violated (p&lt;0.0001), we still proceeded with an ordinal analysis for assessing the distribution of mRS scores and to compare these with analyses of dichotomised mRS scores. In univariate analysis on shift mRS scores, current smokers had a higher likelihood of a favourable outcome, compared with non-smokers (OR 0.88, 95% CI 0.77 to 0.99; p=0.038) (<xref rid="T2" ref-type="table">table 2</xref>, <xref rid="SP2" ref-type="supplementary-material">online supplemental figure S2</xref>). However, the direction of association was reversed in a fully adjusted model with IPTW (adjusted OR 1.15, 95% CI 1.04 to 1.28; p=0.009), indicating current smokers had an unfavourable outcome. This association with poor outcome was consistent across all dichotomised mRS scores, except for severe grades of disability (mRS scores 4–6 and 5–6).</p>
              <supplementary-material id="SP1" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1136/svn-2020-000493.supp1</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="SS1" xlink:href="svn-2020-000493supp001.pdf" content-type="local-data"/>
                </p>
              </supplementary-material>
              <supplementary-material id="SP2" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1136/svn-2020-000493.supp2</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="SS2" xlink:href="svn-2020-000493supp002.pdf" content-type="local-data"/>
                </p>
              </supplementary-material>
              <table-wrap position="float" id="T2">
                <label>Table 2</label>
                <caption>
                  <p>Primary and secondary outcomes at 3 months</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="2" colspan="1">Outcome</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Non-smoking</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Smoking</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="2">Univariate</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="2">Multivariable</td>
                    </tr>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">N=3532</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">N=1008</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">P value</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">P value</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Primary outcome—ordinal mRS</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.88 (0.77 to 0.99)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.038</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.15 (1.04 to 1.28)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.009*</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Secondary outcome—dichotomised mRS</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 1–6 versus 0</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2571/3467 (74.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">728/981 (74.2)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.00 (0.85 to 1.18)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.973</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.24 (1.09 to 1.43)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.002</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 2–6 versus 0–1</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1756/3467 (50.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">469/981 (47.8)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.89 (0.78 to 1.03)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.117</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.18 (1.05 to 1.33)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.007</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 3–6 versus 0–2</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1265/3467 (36.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">319/981 (32.5)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.84 (0.72 to 0.98)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.022</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.18 (1.04 to 1.33)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.009</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 4–6 versus 0–3</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">875/3467 (25.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">187/981 (19.1)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.70 (0.59 to 0.83)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">&lt;0.001</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.98 (0.85 to 1.12)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.741</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 5–6 versus 0–4</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">532/3467 (15.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">111/981 (11.3)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.70 (0.57 to 0.88)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.002</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.01 (0.86 to 1.20)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.889</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Death</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">338/3532 (9.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">71/1008 (7.0)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.72 (0.55 to 0.94)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.015</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.94 (0.77 to 1.16)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.586</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Death or neurological deterioration in 24 hours†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">305/3532 (8.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">87/1008 (8.6)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.00 (0.78 to 1.28)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.997</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.26 (1.03 to 1.54)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.023</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Death or neurological deterioration in 7 days†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">444/3532 (12.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">123/1008 (12.2)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.97 (0.78 to 1.20)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.757</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.18 (0.99 to 1.40)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.059</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Symptomatic ICH‡</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> SITS-MOST criteria</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">56/3532 (1.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">15/1008 (1.5)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.94 (0.53 to 1.67)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.826</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.17 (0.74 to 1.84)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.509</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> NINDS criteria</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">246/3532 (7.0)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">67/1008 (6.6)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.95 (0.72 to 1.26)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.725</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.29 (1.03 to 1.60)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.026</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> ECASS2 criteria</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">160/3532 (4.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">39/1008 (3.9)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.85 (0.59 to 1.21)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.367</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.17 (0.89 to 1.53)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.268</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> ECASS3 criteria</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">73/3532 (2.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">19/1008 (1.9)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.91 (0.55 to 1.52)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.718</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.01 (0.66 to 1.53)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.981</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> IST3 criteria</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">96/3532 (2.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">26/1008 (2.6)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.95 (0.61 to 1.47)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.810</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.06 (0.74 to 1.53)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.747</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Any ICH</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">670/3532 (19.0)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">173/1008 (17.2)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.89 (0.74 to 1.06)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.193</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.09 (0.94 to 1.27)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.248</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Any clinical-reported ICH</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">298/3532 (8.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">77/1008 (7.6)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.90 (0.69 to 1.17)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.417</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.12 (0.91 to 1.38)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.298</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Any adjudicated ICH</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">593/3532 (16.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">155/1008 (15.4)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.90 (0.74 to 1.09)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.287</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">1.11 (0.95 to 1.30)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.174</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Fatal ICH</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">36/3532 (1.0)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8/1008 (0.8)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.78 (0.36 to 1.68)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.520</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.95 (0.52 to 1.73)</td>
                      <td align="char" char="." rowspan="1" valign="top" colspan="1">0.857</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T2_FN1">
                    <p>*The common OR was estimated from an ordinal logistic-regression model and indicates the odds of a decrease of 1 in the modified Rankin Scale (mRS) score.</p>
                  </fn>
                  <fn id="T2_FN2">
                    <p>†Neurological deterioration (≥4 points increase in National Institutes of Health Stroke Scale (NIHSS) score) or death within 24–36 hours.</p>
                  </fn>
                  <fn id="T2_FN3">
                    <p>‡The main definition of symptomatic intracerebral haemorrhage (ICH) used was from Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), as a large local or remote parenchymal intracerebral haemorrhage (&gt;30% of the infarcted area affected by haemorrhage with mass effect or extension outside the infarct) in combination with neurological deterioration from baseline (increase of ≥4 in in the NIHSS score) or death within 36 hours. Symptomatic ICH was also assessed according to other trial criteria (see appendix).</p>
                  </fn>
                  <fn id="T2_FN4">
                    <p>CI, confidence interval; ECASS2 and ECASS 3, second and third European Cooperative Acute Stroke Studies; IST3, third International Stroke Study; NINDS, National Institute of Neurological Disorders and Stroke; OR, odds ratio.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>There was no significant association between smoking and different definitions of sICH, except for NINDS criteria (OR 1.29, 95% CI 1.03 to 1.60; p=0.003) (<xref rid="T2" ref-type="table">table 2</xref>, <xref rid="F1" ref-type="fig">figure 1</xref>). Sensitivity analysis undertaken to explore potential confounders indicated age, sex and baseline NIHSS were the key factors influencing the direction of association (<xref rid="T3" ref-type="table">table 3</xref>); their exclusion from models produced comparable direction and magnitude of association between smoking and functional outcomes seen in univariate analysis (OR 0.96, 95% CI 0.85 to 1.09; p=0.557).</p>
              <fig position="float" id="F1">
                <label>Figure 1</label>
                <caption>
                  <p>Forest plot for symptomatic
intracerebral haemorrhage (ICH) variables at 90 days. ECASS2/3, second and third European Cooperative Acute
Stroke Studies; IST3, third International Stroke Trial; NINDS, National Institute of Neurological Disorders and
Stroke; SITS-MOST, Safe Implementation of Thrombolysis in
Stroke-Monitoring Study.</p>
                </caption>
                <graphic xlink:href="svn-2020-000493f01" position="float"/>
              </fig>
              <table-wrap position="float" id="T3">
                <label>Table 3</label>
                <caption>
                  <p>Logistic regression models for primary outcome, with variable exclusions</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Outcome</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Models</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">P value</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="4" colspan="1">Ordinal mRS</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Model 1</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">1.23 (1.07 to 1.40)</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">0.003</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Model 2</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">1.26 (1.10 to 1.43)</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Model 3</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">1.12 (0.98 to 1.27)</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">0.088</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Model 4</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">0.96 (0.85 to 1.09)</td>
                      <td valign="top" align="char" char="." rowspan="1" colspan="1">0.557</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T3_FN1">
                    <p>Model 1: fully adjusted for sex, age, ethnic group, baseline National Institutes of Health Stroke Scale (NIHSS), baseline systolic blood pressure, history of hypertension, acute coronary syndrome, other heart disease, diabetes mellitus, hypercholesterolaemia, prior use of antiplatelet use, anticoagulant use, glucose lowering agent, lipid lowering agent, modified Rankin Scale (mRS) before stroke.</p>
                  </fn>
                  <fn id="T3_FN2">
                    <p>Model 2: variables in model 1 with exclusion of sex.</p>
                  </fn>
                  <fn id="T3_FN3">
                    <p>Model 3: variables in model 1 with exclusion of age and sex.</p>
                  </fn>
                  <fn id="T3_FN4">
                    <p>Model 4: variables in model 1 with exclusion of age, sex and baseline NIHSS score.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>In these secondary analyses of the large ENCHANTED database, we have shown that smokers had a poor functional outcome after treatment with intravenous thrombolysis for AIS. The adverse outcome was also reflected in greater odds of early neurological deterioration, but there was no clear association of smoking and sICH. The discordant results across the other studies on this topic may relate to incomplete adjustment for confounding variables, in particular neurological severity.</p>
              <p>The finding that smokers were younger and had more cardiovascular risk factors than non-smokers with AIS, and in having a greater likelihood of large-vessel occlusion or cardioembolism, is consistent with other studies,<xref rid="R7" ref-type="bibr">7 32</xref> suggesting an acceleration of atherosclerosis and thrombus formation from smoking.<xref rid="R33" ref-type="bibr">33–37</xref> However, the so-called ‘smoking-thrombolysis paradox’, promoted in relation to a potential increase in the efficacy of thrombolysis in smokers,<xref rid="R16" ref-type="bibr">16 37 38</xref> may have been influenced by systematic errors and/or residual confounding,<xref rid="R17" ref-type="bibr">17</xref> particularly in relation to neurological severity, as we have shown. A large (n=10 825) multicentre prospective study of AIS has also shown that current and recent smoking was associated with unfavourable functional outcome,<xref rid="R7" ref-type="bibr">7</xref> while a Taiwanese registry study found that smokers had twofold greater mortality and prolonged disability after stroke.<xref rid="R38" ref-type="bibr">38</xref> These findings support our findings where we used a propensity score approach to adjust covariate confounders between smokers and non-smokers.</p>
              <p>Several potential mechanisms could explain the poor prognosis in patients who had thrombolysed AIS who smoke. Smoking may compromise recovery due to abnormal cardiopulmonary function,<xref rid="R6" ref-type="bibr">6 7</xref> while also specific adverse effects on the vascular endothelium that could inhibit restorative processes in the brain.<xref rid="R39" ref-type="bibr">39</xref> An increase in haematocrit may potentially increase resistance to blood flow and oxygen supply.<xref rid="R40" ref-type="bibr">40</xref> Further imaging studies defining the relation of smoking and post-thrombolysis recanalisation status may clarify such mechanistic processes.</p>
              <p>Key strengths of this study include the use of data derived from an international, multicentre, study, which had a rigorous protocol, standardised data collection procedures, and objective outcome measures. The large sample size and use of multivariable models with propensity score matching adjustment of known covariates offered an advantage of reducing the influence of confounding. We recognise, however, that the inclusion of clinical trial participants with predominantly mild-to-moderate AIS from Asia may raise concerns over the generalisability of these results. While other studies have shown a dose-dependent pattern of smoking,<xref rid="R41" ref-type="bibr">41 42</xref> we were limited in only being able to use a simple binary measure of this exposure without any data on the frequency, duration and time from cessation of smoking. Finally, as these analyses were not prespecified, they are prone to random error and residual confounding.</p>
              <p>In summary, our study has shown that smokers adversely influence functional recovery in patients who had thrombolysed AIS, compared with non-smokers.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>Dr Wang is supported by grants from the National Heart Foundation (102117) and New South Wales Health. Dr Yang is supported by grants from National Natural Science Foundation of China (81870940). Dr Robinson is a National Institute for Health Research Senior Investigator. Dr Anderson holds a Senior Investigator Fellowship of the National Health and Medical Research Council of Australia.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> CA contributed to study design, organisation, execution, statistical review and review and critique of the report. LS1 (L Sun) contributed to study execution and writing of the report. LS2 (L Song) contributed to study design, review and critique of the report. XW contributed to study design, data analysis and review and critique of the report. JY, RIL, TR, PML, HA, BO and JC contributed to study organisation, execution and review and critique of the report.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This study is funded by the National Health and Medical Research Council (NHMRC) of Australia (Project Grant 1020462), the Stroke Association of the United Kingdom (Reference TSA 2012/01), and the National Council for Scientific and Technological Development of Brazil (CNPq grant number 467322/2014-7).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Disclaimer:</bold> The views expressed in the article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> RTL reports personal fees from Covidien and Pfizer; HA reports lecture fees from Takeda, Daiichi Sankyo, Astellas, and Aska Pharmaceuticals; outside the submitted work; JC reports research grants and lecture fees from Servier for the ADVANCE trial and post-trial follow-up; BO reports receiving fees for service on the data and safety monitoring committee of the THALES (ticagrelor) trial. CA reports personal lecture fees and travel support, and grants paid to his institution, from Takeda China.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Data are available upon reasonable request. Individual deidentified participant data used in these analyses can be shared by formal request with protocol and statistical analysis plan from any qualified investigator to the Research Office of The George Institute for Global Health, Australia. A tailored dataset specific to the research question will be shared for 6 months, and the data can be only accessed by qualified statisticians for the proposed analysis.</p>
            </sec>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not required.</p>
              </sec>
              <sec>
                <title>Ethics approval</title>
                <p content-type="ethics-approval">Every ethics committee at the participating centers. The study protocol was approved by the appropriate Ethics Committee at each participating hospital, and written informed consent was obtained from each patient or an appropriate surrogate.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Markidan</surname><given-names>J</given-names></string-name>, <string-name><surname>Cole</surname><given-names>JW</given-names></string-name>, <string-name><surname>Cronin</surname><given-names>CA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking and risk of ischemic stroke in young men</article-title>. <source>Stroke</source><year>2018</year>;<volume>49</volume>:<fpage>1276</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.117.018859</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/29674522?><pub-id pub-id-type="pmid">29674522</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ueshima</surname><given-names>H</given-names></string-name>, <string-name><surname>Choudhury</surname><given-names>SR</given-names></string-name>, <string-name><surname>Okayama</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cigarette smoking as a risk factor for stroke death in Japan: nippon DATA80</article-title>. <source>Stroke</source><year>2004</year>;<volume>35</volume>:<fpage>1836</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000131747.84423.74</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15166389?><pub-id pub-id-type="pmid">15166389</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolf</surname><given-names>PA</given-names></string-name>, <string-name><surname>D'Agostino</surname><given-names>RB</given-names></string-name>, <string-name><surname>Kannel</surname><given-names>WB</given-names></string-name></person-group>. <article-title>Cigarette smoking as a risk factor for stroke</article-title>. <source>JAMA</source><year>1988</year>;<volume>259</volume>:<fpage>1025</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1988.03720070025028</pub-id><pub-id pub-id-type="pmid">3339799</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ding</surname><given-names>N</given-names></string-name>, <string-name><surname>Sang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases</article-title>. <source>J Am Coll Cardiol</source><year>2019</year>;<volume>74</volume>:<fpage>498</fpage>–<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2019.05.049</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31345423?><pub-id pub-id-type="pmid">31345423</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>JL</given-names></string-name>, <string-name><surname>Morris</surname><given-names>JK</given-names></string-name>, <string-name><surname>Wald</surname><given-names>NJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Mortality in relation to TAR yield of cigarettes: a prospective study of four cohorts</article-title>. <source>BMJ</source><year>1995</year>;<volume>311</volume>:<fpage>1530</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.311.7019.1530</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/8520394?><pub-id pub-id-type="pmid">8520394</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Weir</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Saver</surname><given-names>JL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of smoking status on outcome after acute ischemic stroke</article-title>. <source>Cerebrovasc Dis</source><year>2006</year>;<volume>21</volume>:<fpage>260</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1159/000091224</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16446540?><pub-id pub-id-type="pmid">16446540</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matsuo</surname><given-names>R</given-names></string-name>, <string-name><surname>Ago</surname><given-names>T</given-names></string-name>, <string-name><surname>Kiyuna</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking status and functional outcomes after acute ischemic stroke</article-title>. <source>Stroke</source><year>2020</year>;<volume>51</volume>:<fpage>846</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.119.027230</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31896344?><pub-id pub-id-type="pmid">31896344</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lees</surname><given-names>KR</given-names></string-name>, <string-name><surname>Emberson</surname><given-names>J</given-names></string-name>, <string-name><surname>Blackwell</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials</article-title>. <source>Stroke</source><year>2016</year>;<volume>47</volume>:<fpage>2373</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.116.013644</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27507856?><pub-id pub-id-type="pmid">27507856</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Powers</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Rabinstein</surname><given-names>AA</given-names></string-name>, <string-name><surname>Ackerson</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart Association/American stroke association</article-title>. <source>Stroke</source><year>2019</year>;<volume>50</volume>:<fpage>e344</fpage>–<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1161/STR.0000000000000211</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31662037?><pub-id pub-id-type="pmid">31662037</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kwiatkowski</surname><given-names>TG</given-names></string-name>, <string-name><surname>Libman</surname><given-names>RB</given-names></string-name>, <string-name><surname>Frankel</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke Study Group</article-title>. <source>N Engl J Med</source><year>1999</year>;<volume>340</volume>:<fpage>1781</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199906103402302</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/10362821?><pub-id pub-id-type="pmid">10362821</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>IST-3 collaborative group</collab></person-group>. <article-title>Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial</article-title>. <source>Lancet Neurol</source><year>2013</year>;<volume>12</volume>:<fpage>768</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(13)70130-3</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23791822?><pub-id pub-id-type="pmid">23791822</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Saver</surname><given-names>JL</given-names></string-name></person-group>. <article-title>The smoking-thrombolysis paradox and acute ischemic stroke</article-title>. <source>Neurology</source><year>2005</year>;<volume>65</volume>:<fpage>293</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1212/01.WNL.0000168163.72351.f3</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16043802?><pub-id pub-id-type="pmid">16043802</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>SC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of clopidogrel by smoking status on secondary stroke prevention</article-title>. <source>Circulation</source><year>2017</year>;<volume>135</volume>:<fpage>315</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.024957</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28093495?><pub-id pub-id-type="pmid">28093495</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Song</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clopidogrel and ischemic stroke outcomes by smoking status: smoker's paradox?</article-title><source>J Neurol Sci</source><year>2017</year>;<volume>373</volume>:<fpage>41</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2016.12.025</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28131222?><pub-id pub-id-type="pmid">28131222</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ali</surname><given-names>SF</given-names></string-name>, <string-name><surname>Smith</surname><given-names>EE</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Paradoxical association of smoking with in-hospital mortality among patients admitted with acute ischemic stroke</article-title>. <source>J Am Heart Assoc</source><year>2013</year>;<volume>2</volume>:<elocation-id>e000171</elocation-id>. <pub-id pub-id-type="doi">10.1161/JAHA.113.000171</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23782919?><pub-id pub-id-type="pmid">23782919</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kufner</surname><given-names>A</given-names></string-name>, <string-name><surname>Nolte</surname><given-names>CH</given-names></string-name>, <string-name><surname>Galinovic</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke</article-title>. <source>Stroke</source><year>2013</year>;<volume>44</volume>:<fpage>407</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.112.662148</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23287785?><pub-id pub-id-type="pmid">23287785</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aune</surname><given-names>E</given-names></string-name>, <string-name><surname>Røislien</surname><given-names>J</given-names></string-name>, <string-name><surname>Mathisen</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The "smoker's paradox" in patients with acute coronary syndrome: a systematic review</article-title>. <source>BMC Med</source><year>2011</year>;<volume>9</volume>:<elocation-id>97</elocation-id>. <pub-id pub-id-type="doi">10.1186/1741-7015-9-97</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21861870?><pub-id pub-id-type="pmid">21861870</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schlemm</surname><given-names>L</given-names></string-name>, <string-name><surname>Kufner</surname><given-names>A</given-names></string-name>, <string-name><surname>Boutitie</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Current Smoking Does Not Modify the Treatment Effect of Intravenous Thrombolysis in Acute Ischemic Stroke Patients-A Post-hoc Analysis of the WAKE-UP Trial</article-title>. <source>Front Neurol</source><year>2019</year>;<volume>10</volume>:<elocation-id>1239</elocation-id>. <pub-id pub-id-type="doi">10.3389/fneur.2019.01239</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31824412?><pub-id pub-id-type="pmid">31824412</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anderson</surname><given-names>CS</given-names></string-name>, <string-name><surname>Woodward</surname><given-names>M</given-names></string-name>, <string-name><surname>Arima</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the enhanced control of hypertension and thrombolysis strokE stuDy (enchanted)</article-title>. <source>Int J Stroke</source><year>2015</year>;<volume>10</volume>:<fpage>1313</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/ijs.12602</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26283139?><pub-id pub-id-type="pmid">26283139</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>VK</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment</article-title>. <source>Int J Stroke</source><year>2015</year>;<volume>10</volume>:<fpage>778</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1111/ijs.12486</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/25832995?><pub-id pub-id-type="pmid">25832995</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anderson</surname><given-names>CS</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>T</given-names></string-name>, <string-name><surname>Lindley</surname><given-names>RI</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Low-Dose versus standard-dose intravenous alteplase in acute ischemic stroke</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>2313</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1515510</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27161018?><pub-id pub-id-type="pmid">27161018</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anderson</surname><given-names>CS</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lindley</surname><given-names>RI</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial</article-title>. <source>Lancet</source><year>2019</year>;<volume>393</volume>:<fpage>877</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(19)30038-8</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30739745?><pub-id pub-id-type="pmid">30739745</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anderson</surname><given-names>CS</given-names></string-name>, <string-name><surname>Woodward</surname><given-names>M</given-names></string-name>, <string-name><surname>Arima</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Statistical analysis plan for evaluating different intensities of blood pressure control in the enhanced control of hypertension and thrombolysis strokE stuDy</article-title>. <source>Int J Stroke</source><year>2019</year>;<volume>14</volume>:<fpage>555</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1747493018806170</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30299230?><pub-id pub-id-type="pmid">30299230</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wahlgren</surname><given-names>N</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>N</given-names></string-name>, <string-name><surname>Dávalos</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in Stroke-Monitoring study (SITS-MOST): an observational study</article-title>. <source>Lancet</source><year>2007</year>;<volume>369</volume>:<fpage>275</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60149-4</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/17258667?><pub-id pub-id-type="pmid">17258667</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group</collab></person-group>. <article-title>Tissue plasminogen activator for acute ischemic stroke</article-title>. <source>N Engl J Med</source><year>1995</year>;<volume>333</volume>:<fpage>1581</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199512143332401</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/7477192?><pub-id pub-id-type="pmid">7477192</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hacke</surname><given-names>W</given-names></string-name>, <string-name><surname>Kaste</surname><given-names>M</given-names></string-name>, <string-name><surname>Fieschi</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). second European-Australasian acute stroke study Investigators</article-title>. <source>Lancet</source><year>1998</year>;<volume>352</volume>:<fpage>1245</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(98)08020-9</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/9788453?><pub-id pub-id-type="pmid">9788453</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>IST-3 collaborative group</collab>, <string-name><surname>Sandercock</surname><given-names>P</given-names></string-name>, <string-name><surname>Wardlaw</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial</article-title>. <source>Lancet</source><year>2012</year>;<volume>379</volume>:<fpage>2352</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60768-5</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22632908?><pub-id pub-id-type="pmid">22632908</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hacke</surname><given-names>W</given-names></string-name>, <string-name><surname>Kaste</surname><given-names>M</given-names></string-name>, <string-name><surname>Bluhmki</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>359</volume>:<fpage>1317</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0804656</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18815396?><pub-id pub-id-type="pmid">18815396</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robins</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hernán</surname><given-names>MA</given-names></string-name>, <string-name><surname>Brumback</surname><given-names>B</given-names></string-name></person-group>. <article-title>Marginal structural models and causal inference in epidemiology</article-title>. <source>Epidemiology</source><year>2000</year>;<volume>11</volume>:<fpage>550</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1097/00001648-200009000-00011</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/10955408?><pub-id pub-id-type="pmid">10955408</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haviland</surname><given-names>A</given-names></string-name>, <string-name><surname>Nagin</surname><given-names>DS</given-names></string-name>, <string-name><surname>Rosenbaum</surname><given-names>PR</given-names></string-name></person-group>. <article-title>Combining propensity score matching and group-based trajectory analysis in an observational study</article-title>. <source>Psychol Methods</source><year>2007</year>;<volume>12</volume>:<fpage>247</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1037/1082-989X.12.3.247</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/17784793?><pub-id pub-id-type="pmid">17784793</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name><surname>Rheta</surname><given-names>E</given-names></string-name>, <string-name><surname>Lanehart PRdG</surname><given-names>ESK</given-names></string-name>, <string-name><surname>Bellara</surname><given-names>AP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Propensity score analysis and assessment of propensity score approaches using SAS procedures [online]</article-title>. Available: <uri xlink:href="http://supportsascom/resources/papers/proceedings12/314-2012pdf">http://supportsascom/resources/papers/proceedings12/314-2012pdf</uri></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ntaios</surname><given-names>G</given-names></string-name>, <string-name><surname>Milionis</surname><given-names>H</given-names></string-name>, <string-name><surname>Vemmos</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Small-Vessel occlusion versus large-artery atherosclerotic strokes in diabetics: patient characteristics, outcomes, and predictors of stroke mechanism</article-title>. <source>Eur Stroke J</source><year>2016</year>;<volume>1</volume>:<fpage>108</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1177/2396987316647856</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31008272?><pub-id pub-id-type="pmid">31008272</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qian</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ye</surname><given-names>D</given-names></string-name>, <string-name><surname>Wu</surname><given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Role of cigarette smoking in the development of ischemic stroke and its subtypes: a Mendelian randomization study</article-title>. <source>Clin Epidemiol</source><year>2019</year>;<volume>11</volume>:<fpage>725</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2147/CLEP.S215933</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31616189?><pub-id pub-id-type="pmid">31616189</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ji</surname><given-names>R</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Current smoking is associated with extracranial carotid atherosclerotic stenosis but not with intracranial large artery disease</article-title>. <source>BMC Neurol</source><year>2017</year>;<volume>17</volume>:<elocation-id>120</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12883-017-0873-7</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28651523?><pub-id pub-id-type="pmid">28651523</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsson</surname><given-names>SC</given-names></string-name>, <string-name><surname>Burgess</surname><given-names>S</given-names></string-name>, <string-name><surname>Michaëlsson</surname><given-names>K</given-names></string-name></person-group>. <article-title>Smoking and stroke: a Mendelian randomization study</article-title>. <source>Ann Neurol</source><year>2019</year>;<volume>86</volume>:<fpage>468</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1002/ana.25534</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31237718?><pub-id pub-id-type="pmid">31237718</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barua</surname><given-names>RS</given-names></string-name>, <string-name><surname>Sy</surname><given-names>F</given-names></string-name>, <string-name><surname>Srikanth</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation</article-title>. <source>Arterioscler Thromb Vasc Biol</source><year>2010</year>;<volume>30</volume>:<fpage>75</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.109.195024</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/19815816?><pub-id pub-id-type="pmid">19815816</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Messner</surname><given-names>B</given-names></string-name>, <string-name><surname>Bernhard</surname><given-names>D</given-names></string-name></person-group>. <article-title>Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis</article-title>. <source>Arterioscler Thromb Vasc Biol</source><year>2014</year>;<volume>34</volume>:<fpage>509</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.113.300156</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24554606?><pub-id pub-id-type="pmid">24554606</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>H-K</given-names></string-name>, <string-name><surname>Huang</surname><given-names>C-Y</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y-T</given-names></string-name></person-group>. <article-title>Smoking paradox in stroke survivors?: uncovering the truth by interpreting 2 sets of data</article-title>. <source>Stroke</source><year>2020</year>;<volume>51</volume>:<elocation-id>STROKEAHA119027012</elocation-id>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.119.027012</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32151234?></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>RL</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>JS</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>TG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cigarette smoking decreases cerebral blood flow suggesting increased risk for stroke</article-title>. <source>JAMA</source><year>1983</year>;<volume>250</volume>:<fpage>2796</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1983.03340200030024</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/6644957?><pub-id pub-id-type="pmid">6644957</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>B</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J-F</given-names></string-name></person-group>. <article-title>“Smoking paradox” is not true in patients with ischemic stroke: a systematic review and meta-analysis</article-title>. <source>J Neurol</source><year>2019</year>. <pub-id pub-id-type="doi">10.1007/s00415-019-09596-3</pub-id>. [Epub ahead of print: <comment>29 Oct 2019</comment>].</mixed-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Peto</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies</article-title>. <source>Lancet</source><year>2015</year>;<volume>386</volume>:<fpage>1447</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00340-2</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26466050?><pub-id pub-id-type="pmid">26466050</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Epstein</surname><given-names>KA</given-names></string-name>, <string-name><surname>Viscoli</surname><given-names>CM</given-names></string-name>, <string-name><surname>Spence</surname><given-names>JD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking cessation and outcome after ischemic stroke or TIA</article-title>. <source>Neurology</source><year>2017</year>;<volume>89</volume>:<fpage>1723</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000004524</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28887378?><pub-id pub-id-type="pmid">28887378</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
